Skip to main content
SpringerLink
Log in

Treatment Options in Hormone-Refractory Prostate Cancer

Current and Future Approaches

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Prostate cancer is the second leading cause of cancer mortality among men in Western countries. The initial treatment of advanced prostate cancer is suppression of testicular androgen production by medical or surgical castration, but nearly all men with metastases will develop disease progression. Patients with hormone refractory prostate cancer (HRPC) have a median survival of approximately 18 months and no therapy has yet demonstrated a definitive survival advantage. However, in the past several years, a number of promising new treatment strategies have emerged.

One of the most important new treatment strategies involves secondary hormonal manipulation after the failure of primary androgen deprivation. This approach is predicated on the recognition that HRPC is a heterogeneous disease and some patients may respond to alternative hormonal interventions despite the presence of castrate levels of testosterone. Until recently, cytotoxic chemotherapy was felt to be relatively ineffective in the treatment of HRPC. Combination regimens incorporating new active agents have demonstrated significant activity in this setting, renewing interest in the use of chemotherapy to treat HRPC.

Recent advances in the understanding of prostate cancer biology have led to the development of drugs directed against precise molecular alterations in the prostate tumour cell. Biologic agents now in development include those capable of altering signal transduction, blocking angiogenesis, inhibiting cell cycle progression, and stimulating apoptosis. In addition, many types of immune therapies are showing promise. Evaluating these agents, and incorporating them into existing regimens, are major goals of ongoing clinical research in advanced prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Greenlee RT, Murray T, Bolden S, et al. Cancer Statistics 2000. CA Cancer J Clin 2000; 50(1): 7–33

    Article  PubMed  CAS  Google Scholar 

  2. Gittes RF. Carcinoma of the prostate. N Engl J Med 1991; 324(4): 236–45

    Article  PubMed  CAS  Google Scholar 

  3. Cabot A. The question of castration for enlarged prostate. Ann Surg 1896; 24: 265

    Article  PubMed  CAS  Google Scholar 

  4. White J. The present position of the surgery of the hypertrophied prostate. Ann Surg 1893; 18: 152

    Article  PubMed  CAS  Google Scholar 

  5. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen, and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–7

    CAS  Google Scholar 

  6. Huggins C, Stevens R, Hodges CV. Studies on prostatic carcinoma: II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg 1941; 43: 209–33

    Article  CAS  Google Scholar 

  7. The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 1984; 311(20): 1281–6

    Article  Google Scholar 

  8. Schellhammer PF. Combined androgen blockade for the treatment of metastatic cancer of the prostate. Urology 1996; 47(5): 622–8

    Article  PubMed  CAS  Google Scholar 

  9. Silver RJ, Straus FH II, Vogelzang NJ, et al. Response to orchiectomy following Zoladex therapy for metastatic prostate carcinoma. Urology 1991; 37(1): 17–21

    Article  PubMed  CAS  Google Scholar 

  10. Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 1993; 11(11): 2167–72

    PubMed  CAS  Google Scholar 

  11. Hussain M, Wolf M, Marshall E, et al. Effects of continued androgen-deprived therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol 1994; 12(9): 1868–75

    PubMed  CAS  Google Scholar 

  12. Fowler JE Jr, Whitmore WF Jr. Considerations for the use of testosterone in systemic chemotherapy for prostatic cancer. Cancer 1982; 49(7): 1373–7

    Article  PubMed  Google Scholar 

  13. Fowler JE Jr, Whitmore WF Jr. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 1981; 126(3): 372–5

    PubMed  Google Scholar 

  14. Manni A, Bartholomew M, Caplan R, et al. Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol 1988; 6(9): 1456–66

    PubMed  CAS  Google Scholar 

  15. Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urology 1995; 46(2): 142–8

    Article  PubMed  CAS  Google Scholar 

  16. Wang MC, Valenzuela LA, Murphy GP, et al. Purification of a human prostate specific antigen. Invest Urol 1979; 17(2): 159–63

    PubMed  CAS  Google Scholar 

  17. Chybowski FM, Keller JJ, Bergstralh EJ, et al. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 1991; 145(2): 313–8

    PubMed  CAS  Google Scholar 

  18. Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 1989; 142(4): 1011–7

    PubMed  CAS  Google Scholar 

  19. Zagars GK, von Eschenbach AC. Prostate-specific antigen: an important marker for prostate cancer treated by external beam radiation therapy. Cancer 1993; 72(2): 538–48

    Article  PubMed  CAS  Google Scholar 

  20. Zietman AL, Dallow KC, McManus PA, et al. Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease. Urology 1996; 47(2): 236–9

    Article  PubMed  CAS  Google Scholar 

  21. Dawson N, Conaway M, Halabi S, et al. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and lukemia Group B study 9181. Cancer 2000; 88(4): 825–34

    Article  PubMed  CAS  Google Scholar 

  22. Kelly WK, Scher HI, Mazumdar M, et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993; 11(4): 607–15

    PubMed  CAS  Google Scholar 

  23. Smith DC, Dunn RL, Strawderman MS, et al. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 1998; 16(5): 1835–43

    PubMed  CAS  Google Scholar 

  24. Small E, McMillan A, Meyer M, et al. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain endpoints and survival. J Clin Oncol 2001; 19(5): 1304–11

    PubMed  CAS  Google Scholar 

  25. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17(11): 3461–7

    PubMed  CAS  Google Scholar 

  26. Eisenberger MA, Nelson WG. How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution! J Natl Cancer Inst 1996; 88(12): 779–81

    Article  PubMed  CAS  Google Scholar 

  27. Tannock IF, Osaba D, Stockier MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14(6): 1756–64

    PubMed  CAS  Google Scholar 

  28. Kelly WK, Curley T, Leibretz C, et al. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol 1995; 13(9): 2208–13

    PubMed  CAS  Google Scholar 

  29. Storlie JA, Buckner JC, Wiseman GA, et al. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 1995; 76(1): 96–100

    Article  PubMed  CAS  Google Scholar 

  30. Konety BR, Johnson CS, Trump DL, et al. Vitamin D in the prevention and treatment of prostate cancer. Semin Urol Oncol 1999; 17(2): 77–84

    PubMed  CAS  Google Scholar 

  31. Zhao X, Ly LH, Peehl DM, et al. Induction of androgen receptor by lalpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 1999; 140(3): 1205–12

    Article  PubMed  CAS  Google Scholar 

  32. Moore MJ, Osaba D, Murphy K, et al. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 1994; 12(4): 689–94

    PubMed  CAS  Google Scholar 

  33. Wilding G, Chen M, Gelmann EP. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 1989; 14(2): 103–14

    Article  PubMed  CAS  Google Scholar 

  34. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993; 149(3): 607–9

    PubMed  CAS  Google Scholar 

  35. Dupont A, Gomez JL, Cusan L, et al. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 1993; 150(3): 908–13

    PubMed  CAS  Google Scholar 

  36. Figg WD, Sartor O, Cooper MR, et al. Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med 1995; 98(4): 412–4

    Article  PubMed  CAS  Google Scholar 

  37. Small EJ, Srinivas S. The antiandrogen withdrawal syndrome: experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 1995; 76(8): 1428–34

    Article  PubMed  CAS  Google Scholar 

  38. Small EJ, Carroll PR. Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 1994; 43(3): 408–10

    Article  PubMed  CAS  Google Scholar 

  39. Dawson NA, McLeod DG. Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J Urol 1995; 153(6): 1946–7

    Article  PubMed  CAS  Google Scholar 

  40. Bissade NK, Kaczmarek AT. Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbesterol. J Urol 1995; 153(6): 1944–5

    Article  Google Scholar 

  41. Small E, Srinivas S. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 1995; 76(8): 1428–34

    Article  PubMed  CAS  Google Scholar 

  42. Middleman MN, Lush RM, Figg WD. The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate. Pharmacotherapy 1996; 16(3): 376–81

    PubMed  CAS  Google Scholar 

  43. Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995; 332(21): 1393–8

    Article  PubMed  CAS  Google Scholar 

  44. Taplin M-E, Bubley GJ, Ko YT, et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999; 59(11): 2511–5

    PubMed  CAS  Google Scholar 

  45. Tannock I, Gospodarowicz M, Meakin W, et al. Treatment of metastatic prostate cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989; 7(5): 590–7

    PubMed  CAS  Google Scholar 

  46. Dawson NA, Cooper MR, Figg WD, et al. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer 1995; 76(3): 453–62

    Article  PubMed  CAS  Google Scholar 

  47. Sartor O, Cooper M, Weinberger M, et al. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of ‘hormone-refractory’ prostate cancer: toxicity and response. J Natl Cancer Inst 1994; 86(3): 222–7

    Article  PubMed  CAS  Google Scholar 

  48. Small EJ, Baron AD, Fippin L, et al. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 1997; 157(4): 1204–7

    Article  PubMed  CAS  Google Scholar 

  49. Small EJ, Baron A, Bok R. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer 1997; 80(9): 1755–9

    Article  PubMed  CAS  Google Scholar 

  50. Dawson NA, Conaway M, Halabi S, et al. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: Cancer and Leukemia Group B Study 9181. Cancer 2000; 88(4): 825–34

    Article  PubMed  CAS  Google Scholar 

  51. Osborn JL, Smith DC, Trump DL. Megestrol acetate in the treatment of hormone refractory prostate cancer. Am J Clin Oncol 1997; 20(3): 308–10

    Article  PubMed  CAS  Google Scholar 

  52. Joyce R, Fenton MA, Rode P, et al. High-dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 1998; 159(1): 149–53

    Article  PubMed  CAS  Google Scholar 

  53. Scher HI, Liebertz C, Kelly WK. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997; 15(8): 2928–38

    PubMed  CAS  Google Scholar 

  54. Veldscholte J, Berrevoets CA, Mulder E. Studies on the human prostatic cancer cell line LNCaP. J Steroid Biochem Mol Biol 1994; 49(4–6): 341–6

    Article  PubMed  CAS  Google Scholar 

  55. Culig Z, Hobisch A, Cronauer MV, et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 1993; 7(12): 1541

    Article  PubMed  CAS  Google Scholar 

  56. Eichenberger T, Trachtenberg J, Toor P, et al. Ketoconazole: a possible direct cytotoxic effect on prostate carcinoma cells. J Urol 1989; 141(1): 190–1

    PubMed  CAS  Google Scholar 

  57. Nishiyama T, Terunuma M. Hormonal sensitivity following endocrine withdrawal in hormone-refractory prostate cancer. Urol Int 2000; 65(1): 28–31

    Article  PubMed  CAS  Google Scholar 

  58. Crombie C, Raghavan D, Page J, et al. Phase II study of megestrol acetate for metastatic carcinoma of the prostate. Br J Urol 1987; 59(5): 443–6

    Article  PubMed  CAS  Google Scholar 

  59. Patel SR, Kvols LK, Hahn RG, et al. A phase II randomized trial of megestrol acetate or dexamethasone in the treatment of hormonally refractory advanced carcinoma of the prostate. Cancer 1990; 66(4): 655–8

    Article  PubMed  CAS  Google Scholar 

  60. Wasalenko JK, Dawson NA. Management of progressive metastatic prostate cancer. Oncology 1997; 11(10): 1551–60

    Google Scholar 

  61. Eisenberger MA, Simon R, O’Dwyer PJ. Areevaluation of non-hormonal cytotoxic chemotherapy in treatment of prostatic carcinoma. J Clin Oncol 1985; 3(6): 827–41

    PubMed  CAS  Google Scholar 

  62. Tannock IF. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 1985; 3(7): 1013–21

    PubMed  CAS  Google Scholar 

  63. Rearden TP, Small ET, Valore F, et al. Phase II study of mitoxantrone for hormone-refractory metastatic prostate cancer. Proc Am Soc Clin Oncol 1992; 11: 218

    Google Scholar 

  64. Raghavan D, Coorey G, Rosen M, et al. Management of hormone-resistant prostate cancer: an Australian trial. Semin Oncol 1996; 23 (6 Suppl. 14): 20–3

    PubMed  CAS  Google Scholar 

  65. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B trial 9182 study. J Clin Oncol 1999; 17(8): 2506–13

    PubMed  CAS  Google Scholar 

  66. Tew KD, Stearns ME. Estramustine: a nitrogen mustard/steroid with antimicrotubule properties. Pharmacol Ther 1989; 43(3): 299–319

    Article  PubMed  CAS  Google Scholar 

  67. Panda D, Miller HP, Islam K, et al. Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action. Proc Natl Acad Sci U S A 1997; 94(20): 10560–4

    Article  PubMed  CAS  Google Scholar 

  68. Perry CM, McTavish D. Estramustine phosphate sodium: a review of its pharmacodynamics and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging 1995; 7(1): 49–74

    Article  PubMed  CAS  Google Scholar 

  69. de Kernion JN, Murphy GP, Priore R, et al. Comparison of flutamide and Emcyt in hormone-refractory metastatic prostate cancer. Urology 1988; 31(4): 312–7

    Article  PubMed  Google Scholar 

  70. Hudes GR, Greenberg R, Krigel RL, et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 1992; 10(11): 1754–61

    PubMed  CAS  Google Scholar 

  71. Seidman AD, Scher HI, Petrylak D, et al. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol 1992; 147 (3 Pt 2): 931–4

    PubMed  CAS  Google Scholar 

  72. Amato R, Ellerhorst J, Bui C. Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate. Urol Oncol 1995; 1: 168–71

    Article  PubMed  CAS  Google Scholar 

  73. Dimopoulos MA, Panopoulus C, Barnia C, et al. Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology 1997; 50(5): 754–8

    Article  PubMed  CAS  Google Scholar 

  74. Pienta KJ, Redman BG, Bandekar R, et al. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology 1997; 50(3): 401–6

    Article  PubMed  CAS  Google Scholar 

  75. Cruciani G. Phase II oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate: Instituto Oncologico Romagnolo, Gruppo Onco-Urologico. Proc Am Soc Clin Oncol 1998; 17: 329A

    Google Scholar 

  76. Reese D, Burris H, Belledgrun A, et al. A phase I/II study of navelbine (vinorelbine) and estramustine in the treatment of hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 1996; 15: 259

    Google Scholar 

  77. Carles J, Domenech M, Gelabert-Mas A, et al. Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients. Acta Oncol 1998; 37(2): 187–91

    Article  PubMed  CAS  Google Scholar 

  78. Frank S, Amsterdam A, Kelly WK, et al. Platinum-based chemotherapy for patients (pts) with poorly differentiated hormone refractory prostate cancers (HRPC): Response and pathologic correlations. Proc Am Soc Clin Oncol 1995; 14: 232

    Google Scholar 

  79. Colleoni M, Graiff C, Vicario G, et al. Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer. Am J Clin Oncol 1997; 20(4): 383–6

    Article  PubMed  CAS  Google Scholar 

  80. Hudes G, Einhorn L, Ross E, et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 1999; 17(10): 3160–6

    PubMed  CAS  Google Scholar 

  81. Albrecht W Horenblas S, Marechal JM, et al. Randomized phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with hormone escaped progressive metastatic prostate cancer. J Urol 1997; 161: 298

    Google Scholar 

  82. Hudes GR, Nathan F, Khater C, et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997; 15(9): 3156–63

    PubMed  CAS  Google Scholar 

  83. Kreis W, Budman DR, Fetten J, et al. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostatic carcinoma. Ann Oncol 1999; 10(1): 33–8

    Article  PubMed  CAS  Google Scholar 

  84. Petrylak DP, Macarthur RD, O’Connor J, et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 1999; 17(3): 958–67

    PubMed  CAS  Google Scholar 

  85. Savarese D, Taplin ME, Halabi S, et al. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of Cancer and Leukemia Group B Trial 9780. Semin Oncol 1999; 26 (5 Suppl. 17): 39–44

    PubMed  CAS  Google Scholar 

  86. Sinibaldi VJ, Carucci M, Laufer M, et al. Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer. Semin Oncol 1999; 26 (5 Suppl. 17): 45–8

    PubMed  CAS  Google Scholar 

  87. Weitzman A, Shelton G, Zuech N, et al. Phase II study of estramustine (E) combined with docetaxel (D) in patients with androgen-independent prostate cancer (AIPCA). Proc Am Soc Clin Oncol 1999; 18: 355a

    Google Scholar 

  88. Friedland D, Cohen J, Miller R Jr, et al. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 1999; 26 (5 Suppl. 17): 19–23

    PubMed  CAS  Google Scholar 

  89. Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer preliminary results. Semin Oncol 1999; 26 (5 Suppl. 17): 14–8

    PubMed  CAS  Google Scholar 

  90. Smith DC, Esper P, Strawderman M, et al. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 1999; 17(6): 1644–71

    Google Scholar 

  91. Kelly W, Curley T, Slovin S, et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 2001; 19(1): 44–53

    PubMed  CAS  Google Scholar 

  92. Hussain M, Petrylak D, Fisher E, et al. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916. Semin Oncol 1999; 26 (5 Suppl. 17): 55–60

    PubMed  CAS  Google Scholar 

  93. Torti FM, Aston D, Lum BL, et al. Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. J Clin Oncol 1983; 1(8): 477–82

    PubMed  CAS  Google Scholar 

  94. Scher H, Yagoda A, Watson RC, et al. Phase II trial of doxorubicin in bidimensionally measurable prostatic adenocarcinoma. J Urol 1984; 131(6): 1099–102

    PubMed  CAS  Google Scholar 

  95. Logothetis CJ, Samuels ML, von Eschenbach AC, et al. Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. J Clin Oncol 1983; 1(6): 368–79

    PubMed  CAS  Google Scholar 

  96. Laurie JA, Hahn RG, Therneau TM, et al. Chemotherapy for hormonally refractory advanced prostate carcinoma: A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil. Cancer 1992; 69(6): 1440–4

    Article  PubMed  CAS  Google Scholar 

  97. Blumenstein B, Crawford ED, Saiers JH, et al. Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: A Southwest Oncology Group study. J Urol 1993; 150 (2 Pt 1): 411–3

    PubMed  CAS  Google Scholar 

  98. Sella A, Kilbourn R, Amato R, et al. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 1994; 12(4): 683–8

    PubMed  CAS  Google Scholar 

  99. Eilerhorst JA, Tu SM, Amato RJ, et al. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 1997; 3 (12 Pt 1): 2371–6

    Google Scholar 

  100. Raghavan D, Cox K, Pearson BS, et al. Oral cyclophosphamide for the management of hormone refractory prostate cancer. Br J Urol 1993; 72 (5 Pt 1): 625–8

    Article  PubMed  CAS  Google Scholar 

  101. Abell F, Wilkes JD, Divers L, et al. Oral cyclophosphamide (CTX) for hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 1995; 14: 243

    Google Scholar 

  102. von Roemeling R, Fisher H, Horton J. Daily oral cyclophosphamide is effective in hormone-refractory prostate cancer: a PH-I/II pilot study. Proc Am Soc Clin Oncol 1992; 11: 213

    Google Scholar 

  103. Maulard-Durdux C, Dufour B, Hennequin C, et al. Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients. Cancer 1996; 77(6): 1144–8

    Article  PubMed  CAS  Google Scholar 

  104. Small EJ, Srinivas S, Egan B, et al. Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer. J Clin Oncol 1996; 14(5): 1617–25

    PubMed  CAS  Google Scholar 

  105. Agus DB, Scher HI, Higgins B. Response of prostate cancer to anti-HER-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res 1999; 59(19): 4761–4

    PubMed  CAS  Google Scholar 

  106. Craft N, Shostak Y, Carey M, et al. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by HER-2/neu tyrosine kinase. Nature Med 1999; 5(3): 280–5

    Article  PubMed  CAS  Google Scholar 

  107. Reese D, Small EJ, Waldman F, et al. HER2 expression in androgen-independent prostate cancer. Proc Am Soc Clin Oncol 2000; 19: 347a

    Google Scholar 

  108. Ferrer FA, Miller LJ, Andrawis RI. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 1998; 51(1): 161–7

    Article  PubMed  CAS  Google Scholar 

  109. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993; 362(6423): 841–4

    Article  PubMed  CAS  Google Scholar 

  110. Warren RS, Yuan H, Matli MR. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995; 95(4): 1789–97

    Article  PubMed  CAS  Google Scholar 

  111. Mordenti J, Thomsen K, Licko V, et al. Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans. Toxicol Pathol 1999; 27(1): 14–21

    Article  PubMed  CAS  Google Scholar 

  112. Reese D, Frohlich M, Bok R, et al. A phase II trial of humanized monoclonal anti-vascular endothelial growth factor antibody (rhuMAb VEGF) in hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 1999; 18: 351a

    Google Scholar 

  113. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89(17): 1260–70

    Article  PubMed  CAS  Google Scholar 

  114. Pajouh MS, Nagle RB, Breathnack R, et al. Expression of metalloproteinase genes in human prostate cancer. J Cancer Res Clin Oncol 1991; 117(2): 144–50

    Article  PubMed  CAS  Google Scholar 

  115. Lokeshwar BL, Selzer MG, Block NL. Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in expiant cultures: reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. Cancer Res 1993; 53(19): 4493–8

    PubMed  CAS  Google Scholar 

  116. Jung K, Nowak L, Lein M, et al. Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer. Int J Cancer 1997; 74(2): 220–3

    Article  PubMed  CAS  Google Scholar 

  117. Hande K, Wilding G, Ripple G. A phase I study of AG334, a matrix metalloprotease inhibitor, in patients having advanced cancer. Ann Oncol 1998; 9 Suppl. 2: 74

    Article  Google Scholar 

  118. Berger U, Wilson P, McClelland RA, et al. Immunocytochemical detection of 1,25-dihydroxyvitamin D3 receptors in normal human tissues. J Clin Endocrinol Metab 1988; 67(3): 607–13

    Article  PubMed  CAS  Google Scholar 

  119. Miller GJ, Stapleton GE, Ferrara JA, et al. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1alpha,25-dihydroxyvitamin D 3. Cancer Res 1992; 52(3): 515–20

    PubMed  CAS  Google Scholar 

  120. Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25-dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993; 132(5): 1952–60

    Article  PubMed  CAS  Google Scholar 

  121. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? Anticancer Res 1990; 10(5A): 1307–11

    PubMed  CAS  Google Scholar 

  122. Osborn J, Schwartz GG, Smith DC, et al. Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol 1995; 1: 195–8

    Article  PubMed  CAS  Google Scholar 

  123. Wilding G, Ripple G, Fiers J. Phase I trial of 1α-hydroxyvitamin D2 (1α-OH-D2) administered daily. Proc Am Soc Clin Oncol 1998; 17: 829a

    Google Scholar 

  124. Murphy GP, Tjoa BA, Simmons SJ, et al. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 1999; 38(1): 73–38

    Article  PubMed  CAS  Google Scholar 

  125. Eisenberg DM, Kessler RC, Foster C, et al. Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med 1993; 328(4): 246–52

    Article  PubMed  CAS  Google Scholar 

  126. Risberg T, Lund E, Wist E, et al. Cancer patients use of nonproven therapy: a 5-year follow-up study. J Clin Oncol 1998; 16(1): 6–12

    PubMed  CAS  Google Scholar 

  127. DiPaola RS, Zhang H, Lambert GH, et al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med 1998; 339(12): 785–91

    Article  PubMed  CAS  Google Scholar 

  128. Hsieh T, Chen SS, Wang X, et al. Regulation of androgen receptor (AR) and prostate specific antigen (PSA) expression in the androgen-responsive human prostate LNCaP cells by ethanolic extracts of the Chinese herbal preparation, PCSPES. Biochem Mol Biol Int 1997; 42(3): 535–44

    PubMed  CAS  Google Scholar 

  129. Hsieh TC, Ng C, Chang CC, et al. Induction of apoptosis and down-regulation of bcl-6 in mutu I cells treated with ethanolic extracts of the Chinese herbal supplement PC-SPES. Int J Oncol 1998; 13(16): 1199–202

    PubMed  CAS  Google Scholar 

  130. Kubota T, Hisatake J, Hisatake Y, et al. PC-SPES: a unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo. Prostate 2000; 42(3): 163–71

    Article  PubMed  CAS  Google Scholar 

  131. de la Taille A, Hayek OR, Buttyan R, et al. Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: a preliminary investigation on human cell lines and patients. BJU Int 1999; 84(9): 845–50

    PubMed  Google Scholar 

  132. Tiwari RK, Geliebter J, Garikapaty VP, et al. Anti-tumor effects of PC-SPES, an herbal formulation in prostate cancer. In J Oncol 1999; 14(4): 713–9

    CAS  Google Scholar 

  133. Small EJ, Frohlich M, Bok R, et al. A prospective trial of the herbal supplement PC-SPES, in patients with progressive prostate cancer. J Clin Oncol 2000; 18(21): 3595–603

    PubMed  CAS  Google Scholar 

  134. Pfeifer BL, Pirani JF, Hamann SR, et al. PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer. BJU Int 2000; 85(4): 481–5

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No funding was used to assist in the preparation of this manuscript. Dr Harris is now an employee at Genentech, Inc., the manufacturer of trastuzumab.

Author information

Authors and Affiliations

  1. Urologic Oncology Program, Department of Medicine, UCSF Comprehensive Cancer Center, University of California, San Francisco, USA

    Katherine A. Harris &  David M. Reese

Authors
  1. Katherine A. Harris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David M. Reese
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David M. Reese.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harris, K.A., Reese, D.M. Treatment Options in Hormone-Refractory Prostate Cancer. Drugs 61, 2177–2192 (2001). https://doi.org/10.2165/00003495-200161150-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200161150-00003

Keywords

Search

Navigation